Exelixis, Inc
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base. The company also develops next-generation cancer medicines, with zanzalintinib as its lead late-stage pipeline asset, and it partners with companies such as Ipsen and Takeda to extend cabozantinib’s reach outside the United States.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueApproved cabozantinib-based medicines sold in the U.S. for multiple cancer indications.
Royalty income tied to partner sales of cabozantinib outside the U.S. and Japan.
Development reimbursements, product supply revenue, and deferred revenue recognition from partnerships.
Internal development of zanzalintinib and other oncology candidates that are not yet commercialized.
Products
Reported · share of revenue- Product Gross93.6 %
- Collaboration6.1 %
- Cometriq0.3 %
Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Exelixis sells primarily to U.S. specialty pharmacies, wholesalers, hospitals and other organizations that dispense oncology medicines to patients. Outside the U.S., its commercial reach depends heavily on partners such as Ipsen and Takeda, which commercialize cabozantinib in their territories and generate royalties for Exelixis.
Buys CABOMETYX and COMETRIQ for resale into the oncology care system and is the main commercial route in the U.S.
Receive product through distribution channels and use it in treatment settings for approved cancer indications.
Ipsen and Takeda commercialize cabozantinib outside the U.S. and pay royalties and other collaboration-related amounts.
Oncologists, nurses and pharmacists influence prescribing and adoption of cabozantinib therapies.
Partners that support development, supply and commercialization of pipeline and partnered assets.
Strategy
Exelixis is focused on extending the cabozantinib franchise through additional indications, while building zanzalintinib into a new late-stage oncology asset. The company is also broadening its modality mix through partnerships and selective investment, aiming to convert its commercial base into a longer-duration oncology platform.
New approvals can extend the life of the franchise and support revenue growth from the core asset.
A successful late-stage launch would diversify the company beyond cabozantinib.
Partners provide market access and royalty income without requiring Exelixis to build full international infrastructure.
Reliable product supply is essential for a marketed oncology franchise and future launches.
Geography
Q2/2026Exelixis is commercially anchored in the United States, where it markets CABOMETYX and COMETRIQ directly. Internationally, the company relies on Ipsen and Takeda to commercialize cabozantinib in more than 60 countries outside the U.S., so ex-U.S. exposure is largely royalty-based rather than direct sales-based.
Share of the revenue the company reports by geography.
Risks
Exelixis is highly dependent on the commercial performance of CABOMETYX, so any slowdown in uptake, pricing pressure or loss of exclusivity would directly affect revenue. Its pipeline and international economics also depend on clinical success, regulatory approvals and partner execution, while pharmaceutical pricing scrutiny and supply-chain disruption remain important industry-wide risks.
- CABOMETYX concentration riskImpact: HighLikelihood: Medium
The company states that sales related to cabozantinib account for the majority of revenue, so franchise weakness would have an outsized impact.
Exposure: Core commercial revenue base
- Clinical development and regulatory riskImpact: HighLikelihood: Medium
Zanzalintinib and additional cabozantinib indications require successful trials and approvals before they can contribute meaningfully.
Exposure: Pipeline and label expansion
- Drug pricing and reimbursement pressureImpact: HighLikelihood: Medium
U.S. healthcare reforms, rebates and formulary restrictions can reduce realized net prices and access.
Exposure: U.S. commercial oncology market
- Supply chain and manufacturing disruptionImpact: MediumLikelihood: Low
The company relies on third-party GMP manufacturers and global logistics rather than owned plants.
Exposure: Commercial product supply
- Partner dependence outside the U.S.Impact: Medium
Ex-U.S. commercialization and royalty streams rely on Ipsen and Takeda’s execution and market access.
Exposure: International royalty revenues
Accounting
Judgemental itemsGross U.S. sales are reduced by estimated discounts, rebates, chargebacks and returns, so small estimate changes can affect reported revenue.
Impact: Net sales and gross-to-net margin
Upfront fees, milestones and partner royalties are recognized based on contract terms and underlying partner sales, creating uneven quarterly recognition.
Impact: Revenue volatility
R&D and partner-service costs depend on estimates of work performed and obligations incurred.
Impact: Operating expenses and liabilities
A meaningful non-cash expense for a biotech company and sensitive to valuation assumptions.
Impact: Reported operating profit and EPS
Similar listed companies
Publicly listed companies with a comparable business focus.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Apollomics Inc.
APLMW · Pharmaceutical Preparations
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
Esperion Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on oral, once-daily, non-statin medicines for lowering LDL-C and reducing cardiovascular risk.
Ocular Therapeutix, Inc
OCUL · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Last updated: 24/09/2026